ROCK1 and ROCK2 mediate important processes such as cell migration, invasion and metastasis, making them good targets for the development of antitumor agents. Recently, using a fragment-based approach and X-ray crystallography, we reported on the design and synthesis of novel Rho-kinase inhibitors (RKIs). Here, we selected a pair of RKIs, the closely related structural analogs RKI-18 (potent; IC 50 values of 397 nM (ROCK1) and 349 nM (ROCK2)) and RKI-11 (weak/inactive; IC 50 values of 38 mM (ROCK1) and 45 mM (ROCK2)), as chemical probes and determined their effects on cytoskeleton organization, signaling, apoptosis, anchoragedependent and independent growth, migration and invasion. RKI-18 but not RKI-11 suppresses potently the phosphorylation of the ROCK substrate myosin light chain 2 (MLC2) in intact human breast, lung, colon and prostate cancer cells. Furthermore, RKI-18 is highly selective at decreasing the levels of P-MLC2 over those of P-Akt, P-S6 and P-Erk ½. RKI-18 suppresses ROCK-mediated actin fiber formation, following stimulation with LPA as well as p21-activated kinase (PAK)-mediated lamellipodia and filopodia formation following bradykinin or PDGF stimulation. Furthermore, RKI-18 but not RKI-11 inhibits migration, invasion and anchorageindependent growth of human breast cancer cells. The fact that the active ROCK inhibitor RKI-18, but not the inactive closely related structural analog RKI-11 is effective at suppressing malignant transformation suggests that inhibition of ROCK with RKI-18 results in preventing migration, invasion and anchorage-independent growth. The potential of this class of RKIs as anti-tumor agents warrants further advanced preclinical studies.
INTRODUCTION
The Rho-associated kinases 1 and 2 (ROCK1 and ROCK2) are Ser/ Thr kinases that regulate important cellular processes such as cell morphology, shape, adhesion and migration. [1] [2] [3] [4] [5] [6] [7] A major mechanism by which ROCKs affect these processes is through the phosphorylation of myosin light chain (MLC), the MLC phosphatase PP1 regulatory subunit MYPT-1 and Lim kinase, all of which regulate actin-myosin contractility. Phosphorylation of MLC activates it to induce cell migration, 7, 8 whereas phosphorylation of MYPT-1 inhibits dephosphorylation of MLC. 6 Furthermore, phosphorylation of Lim kinase activates it to phosphorylate and inactivate cofilin that is known to suppress migration. 9 The involvement of ROCKs in malignant transformation has been well studied. For example, ROCKs are overexpressed in cancer cells relative to normal cells, and this overexpression is associated with metastasis, poor clinical outcome and shorter survival of cancer patients. 10, 11 Furthermore, depletion of ROCKs inhibits invasion and metastasis of cancer in vitro and in vivo. 10, [12] [13] [14] [15] [16] [17] In contrast, forced expression induces migration and invasion. 14, 18, 19 Further evidence for the involvement of ROCKs comes from the fact that Rho GTPases such as RhoA and RhoC are the immediate activators of ROCKs and their overexpression induces, whereas their depletion inhibits migration, invasion and metastasis. 20, 21 Furthermore, Rho GTPases have been shown to be overexpressed in a variety of cancer types, [22] [23] [24] [25] [26] [27] and at least one of these, RhoC, has been suggested as a prognostic biomarker for metastasis in breast, melanoma and pancreatic cancer. 21, 26, 27 The overwhelming data supporting the contributions of ROCKs and their affecters, Rho GTPases, in metastasis prompted us and others to investigate the possibility of identifying ROCK inhibitors as potential anti-tumor agents. In this report, we describe the ability of novel ROCK inhibitors that we have recently identified 28 to suppress anchorage-independent growth, migration and invasion of cancer cells. We also describe the ability of the ROCK inhibitors to suppress cytoskeletal and cell morphological changes that are associated with migration and invasion.
RESULTS
Identification of a pair of closely related structural analogs RKI-18 (potent) and RKI-11 (weak/inactive) ROCK inhibitors Our recent chemistry efforts using fragment-based drug design coupled with X-ray crystallography resulted in the identification of potent Rho kinase inhibitors (RKIs). 28 In an effort to investigate the effects of these inhibitors on signaling, anchorage-dependent and -independent tumor cell growth, apoptosis, migration and invasion we selected a pair of closely related analogs, one potent and the other weak/inactive RKI. RKI-18 and RKI-11 are structurally very close indazole urea-based analogs where in RKI-18 the indazole urea and the phenyl group are linked by the two carbon ethylene, whereas in RKI-11 they are attached directly without a linker ( Figure 1a ). Figure 1b shows that RKI-18 and RKI-11 inhibited ROCK1 with IC 50 values of 397 nM and 38 mM. Figure 1b also shows that RKI-18 and RKI-11 inhibited ROCK2 with IC 50 values of 349 nM and 45 mM, respectively. Thus, RKI-18 was 96-to 129-fold more potent than RKI-11, providing an ideal pair of potent/ weak (inactive) chemical probes for investigating the effects of ROCK inhibition on malignant transformation. RKI-18 but not RKI-11 inhibits phosphorylation of the ROCK substrate MLC-2 selectively over the phosphorylation of Akt, Erk and S6 kinases in human cancer cells In order to determine the activity of the ROCK inhibitors in intact human cancer cells, MDA-MB-231 breast cancer cells were treated with various concentrations of RKI-11, RKI-18 or vehicle, and their ability to inhibit the phosphorylation of myosin light chain (MLC)-2 at ser19, a well-known substrate of ROCK, was assessed by western blotting as described under Materials and methods. Figure 2a shows that RKI-18 suppressed phospho-MLC-2 levels at concentration as low as 1 mM, whereas RKI-11, consistent with its weak in vitro activity, had no effect at concentrations as high as 30 mM. RKI-18 also inhibited the phosphorylation of MEK (mitogenactivated protein kinase and extracellular signal-regulated kinase) at Ser298, a site known to be phosphorylated by p21-activated kinase (PAK), 29 but RKI-18 was more potent towards inhibiting P-MLC2 than P-MEK. In contrast, RKI-18 had little effects on phospho-Ser-240/244-S6 (mTORC1 substrate) (Figure 2a ). To determine whether RKI-18 can inhibit the phosphorylation of MLC-2 in other human cancer cell lines, we treated three breast (MCF-7, MDA-MB-468 and MDA-MB-231), two lung (A549 and H460), two colon (HT29 and HCT116) and one prostate (DU145) cancer cell lines with either vehicle or RKI-18, and processed the cells for western blotting as described under Materials and methods. Figure 2b shows that in all eight cell lines RKI-18 inhibited the phosphorylation levels of MLC-2. RKI-18 was highly selective for P-MLC-2 over P-S240/244-S6 (mTORC1 substrate), P-S473-Akt (mTORC2 substrate) and P-Erk ½ (MEK substrate) ( Figure 2b ). Taken together, these results demonstrate that RKI-18 is highly selective for ROCK over other kinases such as mTORC1, mTORC2 and MEK. Finally, consistent with the in vitro kinase activity assay results, RKI-18 was much more potent than RKI-11 in intact cells.
RKI-18 but not RKI-11 inhibits LPA-, Bradykinin-and PDGF-induced stress fiber formation, filopodia and lamellipodia, respectively Stress fiber formation upon stimulation with LPA (lysophosphatidic acid) is a cytoskeleton re-organization process mediated by the activation of RhoA/ROCK pathway, whereas PDGF stimulation of lamellipodia formation is mediated by the RAC1/ PAK pathway, and bradykinin stimulation of filopodia (spikes) formation is mediated by the CDC42/PAK pathway. 30 To determine the effects of our RKIs on these morphological changes, we starved NIH 3T3 cells and treated them with either RKI-11, RKI-18 or vehicle prior to stimulating them with either LPA, PDGF or bradykinin, and then staining the cells with phalloidin as described under Materials and methods. Figure 3 shows that RKI-18 but not RKI-11 inhibited LPA-induced stress fiber formation, bradykinin-induced filopodia formation and PDGF-induced lamellipodia formation ( Figure 3 ). The ability of RKI-18 to inhibit the formation of actin stress fiber, filopodia and lamellipodia, cytoskeletal changes that are critical to cell motility, suggests that this inhibitor may interfere with the ability of cancer cells to migrate and invade.
RKI-18 but not RKI-11 inhibits anchorage-independent growth, migration and invasion of human breast cancer cells The ability of cancer cells to metastasize depends on their ability to grow in an anchorage-independent manner, migrate and invade. We, therefore, investigated the effects of RKI-18 and RKI-11 to affect these cancer hallmarks. To this end, we first determined the ability of these compounds to inhibit anchorage-independent growth in soft agar assay as described under Materials and methods. The results from Figure 4a and b demonstrate that RKI-18 inhibited soft agar colony formation of MDA-MB-231 cells with an IC 50 of 8 mM, whereas the closely related analog and less active ROCK inhibitor RKI-11 had little effect at 60 mM on anchorageindependent growth. To determine the effects of RKI-18 and RKI-11 on anchorage-dependent proliferation and survival, MDA-MB-231 cells were treated with increasing concentrations of the inhibitors and processed for MTT assays as well as western blotting as described under Materials and methods. Figure 4c shows that RKI-18 was four-fold less potent at inhibiting anchorage-dependent proliferation (IC 50 ¼ 32 mM) as compared to anchorage-independent growth (IC 50 ¼ 8 mM). Furthermore, RKI-18 treatment (up to 30 mM) of these cells did not induce apoptosis as measured by caspase 3 activation and PARP cleavage (data not shown). These results suggest that the ability of RKI-18 to inhibit the anchorage-independent growth of cancer cell on soft agar is not due to inhibition of anchorage-dependent proliferation and/or induction of apoptosis. We next determined the ability of these compounds to inhibit migration of breast cancer cells in a wound-healing scratch assay as described under Materials and methods. RKI-18 inhibited the migration of MDA-MB-231 cells in a concentration-dependent manner starting at 3 mM (Figure 5a ). In contrast, RKI-11 at 60 mM did not inhibit the migration of these cells (Figure 5a ). The ability of cancer cells to metastasize depends on their ability to invade; we therefore, investigated the ability of RKIs to inhibit invasion as described under Materials and Methods. Figure 5b shows that RKI-18 at 10 mM inhibited the cancer cells from invading through Matrigel by 67%, whereas RKI-11 had no effect on cell invasion at 60 mM.
DISCUSSION
This manuscript describes the anti-migratory and anti-invasive activities of novel ROCK inhibitors as well as their ability to suppress anchorage-independent tumor cell growth and to inhibit cytoskeletal changes associated with migration and invasion. We chose two pairs of inhibitors consisting of potent and weak/ inactive RKIs to be able to demonstrate a correlation between inhibition of the biochemical target and the modulation of the biological phenotypes and cancer hallmarks. RKI-18 and RKI-11 differ by only a two carbon linker, yet RKI-18 is 96-and 129-fold more potent towards ROCK1 and ROCK2, respectively. This was respected in intact breast cancer cells where RKI-18 suppressed the phosphorylation of the ROCK substrate MLC2, whereas RKI-11 had little effect. Importantly, RKI-18 but not RKI-11 inhibited migration, invasion and anchorage-independent growth. The tight correlation between inhibition of ROCK in vitro, inhibition of P-MLC2 levels and suppression of migration, invasion and anchorage-independent tumor cell growth suggest that the ability of RKI-18 to suppress these cancer hallmarks is at least in part due to their ability to inhibit ROCK. RKI-18 inhibited the phosphorylation of MCL2 selectively over the phosphorylation of Akt, Erk 1/2 and S6, suggesting that this inhibitor is not promiscuous. However, RKI-18 also inhibited, although to a lesser extent, the phosphorylation of Ser-298-MEK suggesting that they also inhibit PAK. Consistent with this is the fact that RKI-18 inhibited not only the Rho-ROCK-dependent LPA stimulation of stress fiber formation but also the Rac/PAK-dependent bradykinin stimulation of filopodia formation, as well as the CDC42/PAK-mediated PDGF stimulation of lamellipodia formation. Therefore, the ability of RKI-18 to inhibit migration, invasion and anchorage-independent tumor cell growth may also be mediated at least in part by inhibition of PAK. Inhibition of PAK is desirable as this is a wellvalidated cancer drug discovery target. It is interesting to note here that we have recently reported on another ROCK inhibitor, RKI-1447, with a different pharmacophore than RKI-18, and that was highly selective in its effects on cytoskeletal organization. 31 Indeed RKI-1447 inhibited LPA-but not bradykinin-or PDGFinduced cytoskeletal changes. Consistent with this, RKI-1447 did not inhibit the phosphorylation of S298 on MEK. 31 Finally, RKI-18 did not induce apoptosis and inhibited anchorage-dependent proliferation at concentrations that are much higher than those needed to inhibit anchorage-independent growth, migration and invasion. This suggests that the ability of RKI-18 to inhibit anchorage-independent growth, migration and invasion is not due to inhibition of proliferation and/or induction of apoptosis. This is consistent with a mechanism involving inhibition of ROCKs, kinases known to be involved in migration and invasion, and not proliferation and survival. 6, 32 
MATERIALS AND METHODS ROCK1 and ROCK2 kinase assays
The assay conditions and quantification procedures were exactly the same as described previously by us. 28 Soft agar assay MDA-MB-231 cells were seeded in a 12-well tissue culture plate at 1200 cells per well in regular growth media and 0.3% agar as described by us. 33 The cells were treated with different doses of RKI-11and RKI-18, allowed to grow for 4 weeks, after which the colonies were stained overnight with 1 mg/ml MTT and counted as described by us. 33 
MTT assay
MTT assay was performed to determine the effects of RKIs on anchoragedependent cell proliferation. Briefly, cells were plated in a 96-well tissue culture plate (1200 cells per well) and incubated for 24 h. After incubation, the cells were treated with vehicle or increasing concentrations of RKI-11 or RKI-18 (0.05-50 mM). After 72 h incubation, freshly prepared MTT (2 mg/ ml) was added to each well and incubated for 3 h. After incubation, the plates were read at 540 nm.
Wound-healing-migration assay MDA-MB-231 cells were seeded at 4 Â 10 5 cells per well in a 6-well plate and allowed to grow overnight at 37 1C and 5% CO 2 . The cells were starved for 24 h and scratched. The cells were then treated with different concentrations of RKIs in regular growth media for 24 h. Images of the scratch were acquired at 0 h and 24 h.
Invasion assay
Invasion assay was performed in Corning Transwell inserts coated with Matrigel. MDA-MB-231 cells were seeded at 3.5 Â 10 5 and allowed to grow overnight in a 6-well plate. The cells were treated with either vehicle or different doses of RKIs for 24 h. After treatment, the cells were trypsinized, resuspended and plated in the inserts as described by us previously. 31 The bottom chamber contained 20% FBS as the 'chemoattractant'. The cells were kept in the incubator for 48 h. After incubation, the cells were stained and membrane was quantified exactly the same way as described by us previously. 31 
